In:
Nephron Clinical Practice, S. Karger AG, Vol. 111, No. 4 ( 2009-3-17), p. c260-c264
Abstract:
〈 i 〉 Background/Aims: 〈 /i 〉 The antibody monitoring system (AMS) is a recently developed enzyme-linked immunosorbent assay (ELISA) crossmatch assay to detect donor-specific anti-HLA immunoglobulin G antibodies (DS-HLA Abs). This study was conducted to compare the AMS with the flow cytometric crossmatch (FCXM) test in renal transplant recipients with high panel-reactive antibody (PRA). 〈 i 〉 Methods: 〈 /i 〉 Thirty-two sera were obtained from 10 patients with panel reactivity above 50%. When anti-HLA Ab was detected by ELISA PRA and the matched donor had the corresponding HLA antigen, it was considered to indicate DS-HLA Ab. The results of the AMS assay and FCXM were compared with the DS-HLA Abs. 〈 i 〉 Results: 〈 /i 〉 Twenty-three (71.9%) sera were positive for DS-HLA Abs by ELISA PRA. The AMS assay showed that the number of compatible sera with DS-HLA Abs was 27 (84.4%), and it was significantly concordant (κ = 0.649, p 〈 0.0001). For FCXM, the number of compatible sera with DS-HLA Abs was 26 (81.3%), and it was also significantly concordant (κ = 0.614, p 〈 0.0001). There was a significant degree of concordance between the AMS assay and FCXM in detection of DS-HLA Abs (κ = 0.452, p = 0.010). 〈 i 〉 Conclusion: 〈 /i 〉 The AMS assay is comparable to FCXM in detecting DS-HLA Abs in high PRA recipients.
Type of Medium:
Online Resource
ISSN:
1660-2110
Language:
English
Publisher:
S. Karger AG
Publication Date:
2009
detail.hit.zdb_id:
2098336-0
Permalink